Vaxart Faces Proxy Contest, Urges Shareholder Support for Nominees
VXRT has more than doubled off its 52-week low of $0.261.
Summary
Vaxart is facing a proxy contest from dissident shareholders seeking to replace board members, prompting the company to issue a letter urging support for its current nominees.
Key Events · Corporate Governance and Compliance · VXRT
-
Proxy Contest Announced
Vaxart disclosed a proxy contest for its upcoming Annual Meeting on July 16, 2026, with dissident shareholders nominating three candidates for the Board of Directors.
-
Company Defends Board Nominees
Vaxart issued a letter to shareholders highlighting its clinical and operational progress and urging support for its six company-nominated director candidates, emphasizing their relevant experience.
-
Preliminary Proxy Filed
The company announced it would file its preliminary proxy statement and related materials today in connection with the Annual Meeting.
Analysis · VXRT · Life Sciences
Vaxart has announced a proxy contest ahead of its Annual Meeting on July 16, 2026, where dissident shareholders are attempting to elect three new directors. The company is actively campaigning for its six nominated directors, highlighting clinical and operational progress and emphasizing the need for experienced leadership. This event signals internal conflict and introduces uncertainty regarding the company's future strategic direction and board composition.
At the time of this filing, VXRT was trading at $0.61 on OTC in the Life Sciences sector, with a market capitalization of approximately $147.6M. The 52-week trading range was $0.26 to $0.84. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.